

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

NEW SELECTIVE SYNTHESIS OF 3-BROMOMETHYL-3-CEPHEM ESTERS

I. Miskolczi^a; F. Sztaricskai^b; R. Bognár^b

^a Biogal Pharmaceutical Works, Debrecen ^b Research Group for Antibiotics of the Hungarian Academy of Sciences, Debrecen, HUNGARY

To cite this Article Miskolczi, I. , Sztaricskai, F. and Bognár, R.(1981) 'NEW SELECTIVE SYNTHESIS OF 3-BROMOMETHYL-3-CEPHEM ESTERS', *Organic Preparations and Procedures International*, 13: 5, 315 – 322

To link to this Article: DOI: 10.1080/00304948109356133

URL: <http://dx.doi.org/10.1080/00304948109356133>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NEW SELECTIVE SYNTHESIS OF 3-BROMOMETHYL-3-CEPHEM ESTERS

I. Miskolczi

Biogal Pharmaceutical Works, Debrecen

F. Sztaricskai and R. Bognár*

Research Group for Antibiotics of the Hungarian
Academy of Sciences, 4010 Debrecen, HUNGARY


7-Acylamido-3-halomethyl-3-cephem-4-carboxylic acid esters are potential intermediates for the preparation of the modern, second and third generation cephalosporin molecules. These compounds are generally synthesized by the halogenation of secopenicillins², deacetoxy-cephem-, deacetyl-cephem-,^{3,4} 3-acetoxymethyl-cephem-,^{5,6} or 3-exo-methylene-cephem¹ derivatives. The most common method for the halogenation⁷⁻⁹ involves the bromination of 2-cephem esters with N-bromosuccinimide. The patent literature describes several procedures¹⁰⁻¹³ for the photocatalytic halogenation of 3-methyl-3-cephem 1-oxide esters using N-chloro- or N-bromosuccinimide, N-bromoacetamide, N-chlorophthalimide, 1,3-dibromo-5,5-dimethylhydantion or N-bromocaprolactam. However, most of the above methods for the halogenation at C-3' are not selective enough, leading to the undesired substitution^{11,12} of the C-2 carbon atom, the 7-acylamido side-chain and of the ester group.

Recently, Japanese authors¹³ have reported an efficient and highly selective method for the bromination of 2';2';2'-

trichloroethyl-7-phenylacetamido-3-methyl-3-cephem-4-carboxylate 1-oxide with N-bromosuccinimide (AcOH, 20°C, hv, under nitrogen atmosphere). In our hands, this reaction using the reported conditions gave a mixture of five products (detected by tlc) from which three crystalline compounds, 2',2',2'-trichloroethyl-7-phenylacetamido-3-bromomethyl-3-cephem-4-carboxylate 1-oxide, its 7-D- α -bromo- and 7-L- α -bromo analogues could be separated by column chromatography (Silicagel G, 10:1 dichloromethane-acetone). The structure of the above products was established by $^1\text{H-NMR}$. The remaining two components, formed in traces, could not be isolated. Although this bromination is not selective, the great advantage of this method is that the undesired C-2 derivative forms at most in a very slight extent.

We felt that the bromination reaction of a cephalosporin molecule, having a strong electron-withdrawing ester group and 7-acylamido side-chain, might be even more selective and would yield predominantly the desired C-3'-bromo compound. In order to prove this assumption, 2',2',2'-trichloroethyl-7-trichloroacetamido-3-methyl-3-cephem-4-carboxylate 1-oxide (II) was prepared in excellent yield by the oxidation of the known 2',2',2'-trichloroethyl-7-trichloroacetamido-3-methyl-3-cephem-4-carboxylate (I)^{14,15} with m-chloroperbenzoic acid in chloroform. The product II spontaneously crystallized from the reaction mixture.

Bromination of II was carried out with N-bromosuccinimide in glacial acetic acid with exposure to UV light and



the product, 2',2',2'-trichloro-ethyl-7-trichloroacetamido-3-bromomethyl-3-cephem-4-carboxylate 1-oxide (III) precipitated from the reaction mixture in good yield (61 %). Work up of the mother liquor containing compound III exclusively, increased the yield up to 80 %. Compound III is easily crystallizable and can be stored for several months at room temperature without decomposition.

The selective formation of III from II could be unequivocally established by the comparison of their $^1\text{H-NMR}$ -spectra. The characteristic signal of the C-3 methyl group of II at

2.15 ppm (s, 3H) did not appear in the spectrum of III, which, as expected, contained a singlet at 4.59 ppm (2H), assignable to the CH₂Br methylene group. The exactness of the C₁₂H₉BrCl₆N₂O₅S formula proposed for III was also proved by mass spectral investigations. Besides the most characteristic fragmentations, the isotope distribution of the molecular ions was in good agreement with the presence of the six chlorine and one bromine atoms expected from the above formula.

Reduction of the sulfoxide III with phosphorous tribromide resulted in the formation of the crystalline bromomethyl derivative IV in good yield.

According to our experience, compound III and IV are suitable materials for the synthesis of C-3' substituted cephalosporin derivatives. The highly reactive allylic bromine atom of III and of IV could be readily reacted with nucleophiles, i.e. 1-methyl-1H-5-mercaptotetrazole to obtain V and VI respectively in excellent yield. No significant difference between the reactivity of III and IV was observed nor could $\Delta^3 \rightarrow \Delta^2$ isomerisation under the above conditions. Treatment of V with phosphorous tribromide under the same conditions described for III gave VI, but in significantly lower yield.

Reports in the literature have shown that either the removal or the partial halogenation of the trichloroethyl ester and the trichloroacetamido group of VI can be performed in one step.^{14,15} Both the resulting chloroacetamido deriva-

tive and its deacylated¹⁴⁻¹⁶ analogue might be further derivatized thus providing valuable intermediates or drugs in the cephalosporin series. Investigation of such transformation reactions are being in progress.

EXPERIMENTAL

Melting points were determined in capillary tubes and are uncorrected. ¹H-NMR spectra were recorded with a JEOL MH 100 (100 MHz) instrument in DMSO-d₆ solutions using TMS as an internal reference. Mass spectra were obtained with an AEI MS-902 high resolution spectrometer (70 eV). Thin layer chromatography was accomplished on DC-Alurolle Kieselgel 60F 254 (Merck), using 1:1 benzene-ethyl acetate mixture.

2;2;2'-Trichloroethyl-7-trichloroacetamido-3-methyl-3-cephem-4-carboxylate 1-oxide (II).- A solution of 2.46 g (0.005 M)

of 2;2;2'-trichloroethyl-7-trichloroacetamido-3-methyl-3-cephem-4-carboxylate (I) in chloroform (75 ml) was cooled to 0° and *m*-chloroperbenzoic acid (0.85 g) in chloroform (25 ml) was dropwise added with stirring. The reaction mixture was then stirred at room temperature for 3 hrs, the resulting precipitate was filtered and washed with ether to yield 2.1 g (81.8 %) of II, mp. 218-220° (from dioxane), tlc: R_f 0.60.

Anal. Calcd for C₁₂H₁₀Cl₆N₂O₅S: S, 6.32; N, 5.52; Cl, 41.95.

Found : S, 6.59; N, 5.39; Cl, 41.90.

¹H-NMR: δ 2.15 (s, 3H, -CH₃), 3.86, 3.93 (AB, 2H, J=18 Hz, S-CH₂), 5.13 (d, 1H, J_{6,7}=4.6 Hz, H-6), 5.98 (dd, 1H, H-7), 8.48 (d, 1H, J_{NH,7}=9 Hz, -NH), 5.04, 5.12 (AB, 2H, J=13 Hz, -OCH₂CCl₃).

2;2;2'-Trichloroethyl-7-trichloroacetamido-3-bromomethyl-3-cephem-4-carboxylate 1-oxide (III). - Two g. of II was dissolved in 150 ml of acetic acid by heating. The solution was

cooled to room temperature and treated with N-bromosuccinimide (0.8 g) with exposure to a 400 W UV lamp and stirred for 80 minutes. The resulting precipitate was filtered and washed with ether to yield 1.4 g (60.8 %) of III, mp. 225° (from acetone), tlc: R_f 0.78.

Anal. Calcd for $C_{12}H_9BrCl_6N_2O_5S$: S, 5.47; N, 4.78.

Found : S, 5.47; N, 4.66.

1H -NMR: δ 4.0, 4.08 (AB, 2H, $J=18$ Hz, S- CH_2), 4.59 (s, 2H, - CH_2Br), 5.24 (d, 1H, H-6), 6.07 (dd, 1H, $J_{6,7}=5$ Hz, H-7), 8.62 (d, 1H, $J_{NH,7}=9.0$ Hz, -NH), 5.08, 5.19 (AB, 2H, $J=12$ Hz, - OCH_2CCl_3).

Mass spectrum: 582 (M^+ , 3.9 %); 503 (M-Br, 22 %); 475 (503-CO 100 %); 427 (475-SO, 14 %); 275 (M-307, 94 %); 234 (M-348, 33 %); 186 (M-396, 29 %); 131 (CH_2CCl_3 , 86 %); 117 (CCl_3 , 97 %).

2;2;2'-Trichloroethyl-7-trichloroacetamido-3-bromomethyl-3-cephem-4-carboxylate (IV). - Compound III (1 g) was dissolved in dichloromethane (200 ml) containing phosphorous tribromide (1.5 ml). The solution was kept at room temperature for 3 hrs, extracted with 5% sodium hydrogen carbonate solution and water, dried over $MgSO_4$ and evaporated to dryness. The residue was crystallized from ether to give 0.7 g (71.4 %) of IV, mp. 165°, tlc: R_f 0.87.

Anal. Calcd for $C_{12}H_9BrCl_6N_2O_4S$: S, 5.62; N, 4.91.

Found : S, 5.48; N, 4.58.

1H -NMR: δ 3.58, 3.84 (AB, 2H, $J=18$ Hz, -S- CH_2), 4.41, 4.54 (AB, 2H, $J=12$ Hz, - CH_2Br), 4.83, 5.06 (AB, 2H, $J=12$ Hz, - OCH_2CCl_3), 5.18 (d, 1H, $J_{6,7}=5$ Hz, H-6), 5.78 (dd, 1H, $J_{NH,7}=8.0$ Hz, H-7), 7.60 (d, 1H, -NH).

2;2;2'-Trichloroethyl-7-trichloroacetamido-3-(1-methyl-1H-tetrazol-5-yl)-thio-methyl-3-cephem-4-carboxylate 1-oxide (V).

- To a solution of 1-methyl-1H-5-mercapto-tetrazole (0.116 g, 0.001 M) and triethylamine (0.14 ml) in acetone (20 ml) a solution of III (0.58 g) in acetone (20 ml) were added. After storing at room temperature for 30 min. the reaction mixture was diluted with water and the crystalline product V was isolated by filtration, 0.5 g (80.5 %); mp. 178° (from methanol), tlc: R_f 0.28.

Anal. Calcd for $C_{14}H_{12}Cl_6N_6O_5S_2$: S, 10.32; N, 13.53; Cl, 34.24

Found : S, 10.42; N, 13.46; Cl, 33.67.

1H -NMR: δ 4.28 (s, 3H, N-CH₃), 4.26, 4.46 (AB, 2H, S-CH₂-), 4.64, 5.14 (AB, 2H, -CH₂S), 5.40, 5.60 (AB, 2H, CH₂CCl₃), 5.48 (d, 1H, H-6), 6.44² (dd, 1H, H-7), 9.02 (d, 1H, NH).

2,2,2'-Trichloroethyl-7-trichloroacetamido-3-(1-methyl-1H-tetrazol-5-yl)thio-methyl-3-cephem-4-carboxylate (VI)

a. Preparation of VI from V was performed as described above for the preparation of IV. The yield of VI was 55 %.

b. Preparation of VI from IV and 1-methyl-1H-5-mercapto-tetrazole was carried as described above for the synthesis of V.

After removal of triethylamine hydrobromide by filtration the solution was evaporated to dryness. The residue was dissolved in ethyl acetate and extracted with water. The organic layer was dried over MgSO₄ and evaporated to dryness and the residue was treated with ether to yield amorphous VI (75 %), tlc: R_f 0.80.

Anal. Calcd for $C_{14}H_{12}Cl_6N_6O_4S_2$: S, 10.59; N, 13.88; Cl, 35.15

Found : S, 10.45; N, 13.64; Cl, 34.90.

¹H-NMR: δ 4.28 (s, 3H, -NCH₃), 4.20 (s, 2H, S-CH₂), 4.71, 4.97 (AB, 2H, -CH₂S), 5.40, 5.57 (AB, 2H, CH₂CCl₂), 5.66 (d, 1H, H-6), 6.04 (dd, 1H, J=5 and 7 Hz, H-7), 10.53 (d, 1H, J=7 Hz, NH).

Acknowledgements. -The authors are indebted to the Biogal Pharmaceutical Works (Debrecen), the Hungarian Academy of Sciences and to the Chinoin Pharmaceutical and Chemical Works (Budapest) for support of this work. We also thank Dr. L. Szilágyi and Dr. J. Tamás for the ¹H-NMR and mass spectra and the helpful discussions in their interpretation.

REFERENCES

1. G. A. Koppel, M. D. Kinnich and L. J. Nummy, *J. Am. Chem. Soc.*, 99, 2822 (1977).
2. T. Ishimaru and T. Imamoto, *Bull. Chem. Soc. Japan*, 48, 2989 (1975).
3. Ger. Patent 2,065,708 *Chem. Abst.* 83, 58853k (1975).
4. Ger. Patent 2,015,317 *Chem. Abst.* 74, 100074y (1971).
5. M. L. Edwards and R. C. Erickson, *J. Med. Chem.*, 22, 1416 (1979).
6. H. Yazawa, H. Nakamura, K. Tanaka and K. Kariyone, *Tetrahedron Lett.*, 3991 (1974).
7. J. A. Webber, E. M. Van Heyningen and R. T. Vasileff, *J. Am. Chem. Soc.*, 91, 5674 (1969).
8. J. A. Webber, G. F. Huffman, R. E. Koehler, C. F. Murphy, C. W. Ryan, E. M. Van Heyningen and R. T. Vasileff, *J. Med. Chem.*, 14, 113 (1971).
9. J. A. Webber and R. T. Vasileff, *ibid.*, 14, 1136 (1971).
10. Japan Patent 79,48,793 *Chem. Abst.* 91, 175368g (1979).
11. Ger. Patent 2,042,169 *Chem. Abst.* 75, 88630n (1971).
12. Ger. Patent 2,064,929 *Chem. Abst.* 75, 118332m (1971).
13. Japan Patent 75,76,087 *Chem. Abst.* 84, 4974c (1976).
14. Ger. Patent 24,42,661 *Chem. Abst.* 83, 43355a (1975).
15. Ger. Patent 24,42,663 *Chem. Abst.* 83, 43356a (1975).
16. J. D. Cocker, B. R. Cowley, J. S. G. Cox, S. Eardley, G. I. Gregory, J. K. Lazenby, A. G. Long, J. C. P. Sly, and G. A. Sommerfield, *J. Chem. Soc.*, 5015 (1965).

(Received December 2, 1980; in revised form March 2, 1981)